CoChat

The DOI matches its Crossref record; 100 of the 104 references it cites were found in a registry or an index; 26 of the 52 sources its claims cite were checked for support.

Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: protocol for a pilot fractional factorial trial

Open access

Abstract

Introduction Women with breast cancer who do not adhere to adjuvant endocrine therapy (AET) have increased risks of mortality and recurrence. There are multiple barriers to AET adherence, including medication side-effects, beliefs about medication, memory and psychological distress. We developed four intervention components, each targeting a different barrier. This pilot trial is part of the preparation phase of the Multiphase Optimisation Strategy, and aims to establish key trial parameters, establish intervention component adherence, establish availability and feasibility of outcome and process data, estimate variability in planned outcome measures and estimate cost of developing and delivering each intervention component. Methods and analysis The four intervention components are as follows: short message service text reminders (target: memory); a written information leaflet (target: medication beliefs); a guided self-help Acceptance and Commitment Therapy programme (target: psychological flexibility to reduce distress) and a self-management website (target: side-effect management). To evaluate the feasibility of recruitment, acceptability of the intervention components and the availability of outcome data, we will conduct a multisite, exploratory pilot trial using a 2 4-1 fractional factorial design, with a nested process evaluation. We will randomise 80 women with early-stage breast cancer who have been prescribed AET to one of eight experimental conditions. This will determine the combination of intervention components they receive, ranging from zero to four, with all conditions receiving usual care. Key outcomes of interest include medication adherence and quality of life. Progression to the optimisation phase will be based on predefined criteria for consent rates, patient adherence to intervention components and availability of medication adherence data. Ethics and dissemination The study was reviewed by the Wales Research Authority Research Ethics Committee 3 (21/WA/0322). Written informed consent will be obtained from all patients before randomisation. The results of this trial will be disseminated in a peer-reviewed journal. Trial registration number ISRTCN10487576. © 2023 BMJ Publishing Group. All rights reserved.

Overview

CoChat Summary

## TL;DR

This paper is a protocol for the ROSETA pilot trial, which will test the feasibility of a 4-component behavioural package to support adjuvant endocrine therapy adherence in UK women with early-stage breast cancer. It uses a 24-1 fractional factorial design to estimate component adherence, data availability, variability in outcomes, and costs before deciding whether to proceed to an optimisation trial.

## Key findings

  • The planned pilot will randomise 80 women with early-stage breast cancer to 8 experimental conditions (about 10 per condition) using a 24-1 fractional factorial design, with usual care in all groups.
  • The intervention package has 4 components targeting different adherence barriers: SMS reminders, a medication beliefs leaflet, a guided self-help ACT programme, and a self-management website.
  • Progression to the optimisation phase will be judged using predefined criteria including consent rates, patient adherence to intervention components, and availability of medication adherence data.
  • The study’s primary objective is feasibility/parameter estimation rather than effectiveness; it will estimate rates of eligibility, recruitment, retention, and component adherence, and will present point estimates and 95% CIs for main and interaction effects on adherence and quality of life.

## Methods

  • Design: Multisite, exploratory pilot fractional factorial trial with a nested mixed-methods process evaluation; participants are followed up at 2 and 4 months.
  • Sample/data: 80 adult women using tamoxifen, raloxifene, anastrozole, letrozole, or exemestane for early-stage (1–3a) breast cancer, recruited from five UK NHS hospitals through three routes.
  • Analysis: Primarily descriptive statistics and confidence intervals rather than hypothesis testing; intention-to-treat analysis with adjustment for the stratification factor, plus qualitative interviews analyzed using a rapid evaluation approach.

## Limitations

  • The paper states that the pilot will not examine effectiveness of the intervention components.
  • As a protocol, it reports planned methods and outcomes rather than results; no effectiveness, feasibility, or acceptability findings are stated in the paper.
  • Evident from the text: the trial has 80 participants total and is designed for feasibility/estimation, so it is not powered for definitive effectiveness conclusions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2022-069971

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

14 Valid · 2 Not valid · 15 Not checked · 12 Own results and interpretations

16 more claims · 4 with their cited sources checked

Create a free account to see all 43 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 6
  • Probably not a substantial claim. 17

Create a free account to see these claims.

Citations

Cites

Show all 100 references

Cited by

See all 20

Metadata

Authors
Smith, S. G., Green, S. M. C., Ellison, R., Foy, R., Graham, C. D., Mason, E., French, D. P., Hall, L. H., Wilkes, H., McNaught, E., Raine, E., Walwyn, R., Howdon, D., Clark, J., Rousseau, N., Buxton, J., Moore, S. J. L., Parbutt, C., Velikova, G., Farrin, A., & Collinson, M.
Affiliations
  • University of Leeds (GB)
  • Queen's University Belfast (GB)
  • University of Manchester (GB)
  • Leeds Teaching Hospitals NHS Trust (GB)
Corresponding author
Smith, Samuel G
Venue
BMJ Open
Publisher
BMJ
Published
2023-02
Volume
13
Issue
2
Pages
e069971
ISSN
2044-6055 (ISSN-L)
OpenAlex
W4319078409
Cited by
20
References
104
Citations by year
2026: 3 · 2025: 1 · 2024: 9 · 2023: 7
FWCI
6.15
Type
journal article
Language
en
Open access
Locations
  • BMJ Open (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Research Portal (Queen's University Belfast) (acceptedVersion, cc-by)
  • Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion, cc-by-nc-nd)
  • Research Explorer (The University of Manchester) (acceptedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Manchester Biomedical Research Centre (IS-BRC-1215-20007)
  • National Institute of Health (N/A)
  • Yorkshire Cancer Research (L417, N/A)
  • National Institute for Health (NIHR300588)
Topics
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
Keywords
breast cancer, adjuvant endocrine therapy, medication adherence, behavioral interventions, SMS reminders, medication beliefs, acceptance and commitment therapy, guided self-help, side effect management, psychological distress, quality of life, early breast cancer, intervention optimization, feasibility
MeSH terms
Breast Neoplasms, Female, United Kingdom, Humans, Quality of Life, Randomized Controlled Trials as Topic, Medication Adherence, Acceptance and Commitment Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: protocol for a pilot fractional factorial trial. https://app.cochat.ai/papers/10.1136/bmjopen-2022-069971
The paper
Smith, S. G., Green, S. M. C., Ellison, R., Foy, R., Graham, C. D., Mason, E., French, D. P., Hall, L. H., Wilkes, H., McNaught, E., Raine, E., Walwyn, R., Howdon, D., Clark, J., Rousseau, N., Buxton, J., Moore, S. J. L., Parbutt, C., Velikova, G., . . . Collinson, M. (2023). Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: protocol for a pilot fractional factorial trial. BMJ Open. https://doi.org/10.1136/bmjopen-2022-069971

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.